Pituitary Tumor Surveillance: Pathogenic Correlation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by Cedars-Sinai Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier:
NCT00599092
First received: January 11, 2008
Last updated: July 8, 2009
Last verified: July 2009
  Purpose

The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity in patients harboring pituitary mass lesions of all types.


Condition
Pituitary Tumor

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Pituitary Tumor Surveillance: Pathogenetic Correlation

Resource links provided by NLM:


Further study details as provided by Cedars-Sinai Medical Center:

Biospecimen Retention:   Samples With DNA

whole blood


Estimated Enrollment: 1250
Study Start Date: January 1997
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Detailed Description:

The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome information on patients harboring pituitary mass lesions of all types.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

tertiary referral center

Criteria

Inclusion Criteria:

  • patients with confirmed pituitary disease

Exclusion Criteria:

  • patients who do not have confirmed pituitary disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00599092

Locations
United States, California
Cedars-Sinai Medical Center, Pituitary Center Recruiting
Los Angeles, California, United States, 90048
Contact: Daniel Akers    310-423-3395    daniel.akers@cshs.org   
Contact: Lori Korsakoff, RN    310-423-2411    lori.korsakoff@cshs.org   
Principal Investigator: Shlomo Melmed, MD         
Sponsors and Collaborators
Cedars-Sinai Medical Center
Investigators
Principal Investigator: Shlomo Melmed, MD Cedars-Sinai Medical Center, Pituitary Center
  More Information

No publications provided

Responsible Party: Shlomo Melmed, MD, Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier: NCT00599092     History of Changes
Other Study ID Numbers: 2873, 2873
Study First Received: January 11, 2008
Last Updated: July 8, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Cedars-Sinai Medical Center:
pituitary tumor
recurrence

Additional relevant MeSH terms:
Pituitary Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Hypothalamic Neoplasms
Supratentorial Neoplasms
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hypothalamic Diseases
Pituitary Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on August 26, 2014